Cargando…

USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis

OBJECTIVE: Helicobacter pylori (Hp) is a major risk factor for gastric cancer (GC). Hp promotes DNA damage and proteasomal degradation of p53, the guardian of genome stability. Hp reduces the expression of the transcription factor USF1 shown to stabilise p53 in response to genotoxic stress. We inves...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Lionel, Corre, Sébastien, Michel, Valérie, Le Luel, Krysten, Fernandes, Julien, Ziveri, Jason, Jouvion, Gregory, Danckaert, Anne, Mouchet, Nicolas, Da Silva Barreira, David, Torres, Javier, Camorlinga, Margarita, D'Elios, Mario Milco, Fiette, Laurence, De Reuse, Hilde, Galibert, Marie-Dominique, Touati, Eliette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Helicobacter Pylori
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456735/ https://www.ncbi.nlm.nih.gov/pubmed/31822580 http://dx.doi.org/10.1136/gutjnl-2019-318640

Ejemplares similares

Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines
por: Aebischer, T, et al.
Publicado: (2008)

Helicobacter pylori potentiates epithelial:mesenchymal transition in gastric cancer: links to soluble HB-EGF, gastrin and matrix metalloproteinase-7
por: Yin, Yinfei, et al.
Publicado: (2010)

Protein kinase C isozymes regulate matrix metalloproteinase-1 expression and cell invasion in Helicobacter pylori infection
por: Sokolova, Olga, et al.
Publicado: (2013)

The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention
por: Lee, Yi-Chia, et al.
Publicado: (2013)

CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa
por: Cook, Katherine W, et al.
Publicado: (2014)

Progressive genomic convergence of two Helicobacter pylori strains during mixed infection of a patient with chronic gastritis
por: Cao, Qizhi, et al.
Publicado: (2015)

A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis
por: Zhuang, Yuan, et al.
Publicado: (2015)

A novel human gastric primary cell culture system for modelling Helicobacter pylori infection in vitro
por: Schlaermann, Philipp, et al.
Publicado: (2016)

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
por: Murakami, Kazunari, et al.
Publicado: (2016)

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial
por: Liou, Jyh-Ming, et al.
Publicado: (2016)

Pan-genomic analyses identify key Helicobacter pylori pathogenic loci modified by carcinogenic host microenvironments
por: Noto, Jennifer M, et al.
Publicado: (2018)

Helicobacter pylori infection and micronutrient deficiency in pregnant women: a systematic review and meta-analysis
por: Afsar, Md. Nure Alam, et al.
Publicado: (2020)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
por: Suzuki, Sho, et al.
Publicado: (2020)

Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis
por: Chang, Yen-Lin, et al.
Publicado: (2020)

Assessment of Helicobacter pylori status by examination of gastric mucosal patterns: diagnostic accuracy of white-light endoscopy and narrow-band imaging
por: Glover, Ben, et al.
Publicado: (2021)

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
por: Oster, Paul, et al.
Publicado: (2022)

Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK
por: Pritchard, D. Mark, et al.
Publicado: (2021)

Large-scale, national, family-based epidemiological study on Helicobacter pylori infection in China: the time to change practice for related disease prevention
por: Zhou, Xian-Zhu, et al.
Publicado: (2023)

Helicobacter pylori
por: Harris, A. W. (Adam W.), 1963-
Publicado: (1996)

USF-1 Is Critical for Maintaining Genome Integrity in Response to UV-Induced DNA Photolesions
por: Baron, Yorann, et al.
Publicado: (2012)

p53 Requires the Stress Sensor USF1 to Direct Appropriate Cell Fate Decision
por: Bouafia, Amine, et al.
Publicado: (2014)

DNA Hypermethylation Downregulates Telomerase Reverse Transcriptase (TERT) during H. pylori-Induced Chronic Inflammation
por: Bussière, Françoise I., et al.
Publicado: (2019)

High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
por: Zhao, Zhe, et al.
Publicado: (2022)

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial
por: Mei, Hao, et al.
Publicado: (2022)

Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances
por: Shih, Chih-An, et al.
Publicado: (2022)

High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis
por: Zhou, Ben-Gang, et al.
Publicado: (2023)

The efficacy and safety of Saccharomyces boulardii in addition to antofloxacin-based bismuth quadruple therapy for Helicobacter pylori eradication: a single-center, prospective randomized-control study
por: He, Xiao-Jian, et al.
Publicado: (2023)

Implications of the paradigm shift in management of Helicobacter pylori infections
por: Graham, David Y.
Publicado: (2023)

Therapeutic eradication choices in Helicobacter pylori infection in children
por: Manfredi, Marco, et al.
Publicado: (2023)

Dietary habits and Helicobacter pylori infection: is there an association?
por: Soares, Giovana Alice Sampaio, et al.
Publicado: (2023)

Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection
por: Moss, Steven F., et al.
Publicado: (2023)

Helicobacter pylori in children: think before you kill the bug!
por: Ravikumara, M
Publicado: (2023)

Adequate amounts of probiotics increase the success rate of Helicobacter pylori eradication therapy in children
por: Kakiuchi, Toshihiko
Publicado: (2023)

Update on the second-line treatment of Helicobacter pylori infection: a narrative review
por: Shih, Chih-An, et al.
Publicado: (2023)

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan
por: Howden, Colin W., et al.
Publicado: (2023)

Rescue therapy for refractory Helicobacter pylori infection: current status and future concepts
por: Wang, Song-Wei, et al.
Publicado: (2023)

Significantly higher frequency of Helicobacter suis in patients with idiopathic parkinsonism than in control patients
por: Blaecher, C, et al.
Publicado: (2013)

Multiple Sclerosis: The Role of Cytokines in Pathogenesis and in Therapies
por: Amedei, Amedeo, et al.
Publicado: (2012)

What Is Recent in Pancreatic Cancer Immunotherapy?
por: Niccolai, Elena, et al.
Publicado: (2013)

Editorial: Modulation of the immune system by bacteria: From evasion to therapy
por: de Bernard, Marina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ln9t7ufbtqkt0jikqjhpag1j58